In golden October, international and domestic pharmaceutical exhibitions followed in quick succession. Led by Jianyong Zhang , Board Chairman and General Manager of Qidu Pharmaceutical Group, the company brought competitive products from its six business segments across the full industry chain and successively made a strong showing at both CPHI Milan and PharmChina in Beijing.
Local time, from October 6 to 8, the three-day CPHI Milan was held at Fiera Milano in Milan, Italy. The exhibition brought together more than 2,900 exhibitors and over 60,000 professionals from more than 160 countries and regions. At the booth, Qidu Pharma adopted a minimalist design with clearly defined product zones. The formulations segment covered basic infusion solutions, PP ampoules, oral formulations, a full range of dialysis products, three-chamber bags, and iodinated contrast media; the API segment showcased featured products such as sodium bicarbonate, levocarnitine, thioctic acid, and icodextrin; and the packaging materials segment presented a series of products including combined port caps, prefillable syringes, and high-barrier films. The exhibits included both mature flagship products for international markets and key featured products demonstrating the company’s R&D strength, attracting many visitors to stop by for discussions. Team members received visiting customers with great enthusiasm and professional service, and held in-depth exchanges on topics such as product performance, quality standards, international registration, market access, supply assurance, and customized cooperation. Group leaders focused on receiving customers from more than 50 countries and regions, including Canada, Spain, Germany, South Korea, Saudi Arabia, Malaysia, Singapore, and Algeria, and reached multiple important cooperation intentions on site. While discussing business, the team also gained an in-depth understanding of changing global market demand trends, laying a foundation for further cooperation expansion.
From October 21 to 23, the 93rd China National Pharmaceutical Fair (PharmChina) was held at the China International Exhibition Center in Beijing. This edition of PharmChina brought together nearly 4,000 high-quality enterprises from around the world in pharmaceuticals, healthcare, medical devices, and general health, attracting more than 200,000 professional visitors from home and abroad. Qidu Pharma set up a 120-square-meter custom-designed booth, where its six business segments were showcased together. The pharmaceutical formulations segment covered multiple therapeutic areas and highlighted newly launched products such as Sutoujia® Low Calcium Peritoneal Dialysis Solution (Bicarbonate-G1.5%), Ruihuanjia® Hemofiltration Replacement Fluid of Sodium Citrate, Laifengneng® Lipid Emulsion (10%) / Amino Acids (15) and Glucose (20%) Injection, and Yiruiqing® Rosuvastatin Calcium and Ezetimibe Tablets (I). The featured API segment highlighted core products such as levocarnitine, the hydroxyethyl starch series, and large-particle sodium bicarbonate. The pharmaceutical packaging materials segment displayed several self-developed core products, including COP/PP prefillable syringes, three-layer co-extrusion infusion films, high-barrier pharmaceutical film/pouches, and COP vials. The medical consumables and devices segment exhibited dialysis solutions, dialysis powder, dialysis tubing sets, nursing kits, and other consumables across the entire dialysis chain. The biopharmaceutical segment showcased four innovative product lines: biological culture media, cell therapy, in vitro diagnostic reagents, and antibody protein drugs. The traditional Chinese medicine and general health segment presented Qidu Jinfangge® Qingjin Huatan Tang Granules, a Class 3.1 ancient classical formula product exclusively approved in China. During the fair, Qidu Pharma held multiple in-person product presentations, participated in activities such as the Traditional Chinese Medicine Inheritance and Innovation Product Tour and the “New Star Debut” new product roadshow, and expanded brand exposure through reposts and interactions on its WeChat official account. With its custom-designed booth and rich product matrix, the company further strengthened communication with new and existing partners, and group leaders held in-depth discussions with many domestic and international customers on product access, market cooperation, and other topics.
This year marks the 50th anniversary of the founding of Qidu Pharma. After 50 years of exploration and practice, accumulation and development, the company has built a solid foundation in production capacity, product structure, and market layout, and has formed a strategic framework of “one foundational product, ten therapeutic areas, and six business segments.” It has obtained 297 drug approval numbers, implemented a direct-to-terminal marketing model and the cooperative philosophy of a community with a shared future for industrial and commercial enterprises, cultivated and reserved more than ten branded products with annual sales revenue exceeding RMB 100 million, and exported products to more than 80 countries and regions overseas. Looking ahead, Qidu Pharma will continue to enhance its scientific and technological innovation capabilities, accelerate its internationalization strategy, and solidly implement its high-quality development goals. With a complete full-industry-chain product portfolio, excellent product quality, and professional and considerate services, it will connect with customers worldwide and work hand in hand to create a brighter future for the pharmaceutical and healthcare industry.















Recommended reading
-
January 20, 2025Top Ten Events of Qidu Pharmaceutical Group in 2025 Announced
-
June 17, 2026Qidu Pharma’s intelligent production project for oral preparations with an annual capacity of 10 billion tablets/granules passed the GMP on-site inspection.
-
November 09, 2026“International Qidu · English Leads the Future” Series of Internationalization-Themed Activities Officially Launched
-
November 09, 2026Qidu Pharma Quality Management Work Conference
-
November 09, 2026Qidu Pharma’s First Drug-Loaded Lipid Emulsion Product, Aprepitant Injection, Approved for Marketing
-
October 13, 2026Qidu Pharmaceutical Holds Postdoctoral Completion and Entry Ceremony and Project Report Meeting
-
October 13, 2026Qidu Metrology and Testing Center Passes CNAS Calibration Laboratory On-Site Assessment